This comprehensive review explores the complex mechanisms of cancer cell adhesion, metastasis, and inhibition, emphasizing their critical roles in cancer progression and therapeutic strategies. The review highlights the importance of adhesion molecules such as integrins and cadherins in enabling cancer cells to invade and metastasize. It discusses various inhibition strategies, including integrin-blocking antibodies, small molecule inhibitors targeting FAK and the TGF-β pathway, and combination therapies, which show promise in disrupting focal adhesions and controlling epithelial-mesenchymal transition processes. Key molecular regulators such as FAK, Src, β-catenin, and SMAD4 are identified as important targets for further research and the development of targeted therapies. The review also addresses the challenges and opportunities in targeted therapy approaches, emphasizing the need for personalized medicine and data sharing to improve cancer treatment outcomes. The study demonstrates that adhesion molecule inhibitors significantly reduce cancer cell metastasis across various cancer types, with a 75% reduction in metastatic events upon treatment with integrin inhibitors. The effectiveness of these inhibitors is supported by subgroup analyses showing higher response rates in advanced stages of cancer. The review underscores the importance of prolonged treatment regimens and the need for further research to address challenges such as drug resistance, toxicity, and tumor heterogeneity. The findings highlight the potential of targeting key adhesion molecules to disrupt cancer cell-ECM interactions and control metastasis. The review also emphasizes the importance of advanced preclinical models and clinical trials in validating the efficacy of these therapies. Overall, the study provides valuable insights into the mechanisms governing cancer cell adhesion, metastasis, and inhibition, offering promising therapeutic targets for the development of more effective cancer treatments.This comprehensive review explores the complex mechanisms of cancer cell adhesion, metastasis, and inhibition, emphasizing their critical roles in cancer progression and therapeutic strategies. The review highlights the importance of adhesion molecules such as integrins and cadherins in enabling cancer cells to invade and metastasize. It discusses various inhibition strategies, including integrin-blocking antibodies, small molecule inhibitors targeting FAK and the TGF-β pathway, and combination therapies, which show promise in disrupting focal adhesions and controlling epithelial-mesenchymal transition processes. Key molecular regulators such as FAK, Src, β-catenin, and SMAD4 are identified as important targets for further research and the development of targeted therapies. The review also addresses the challenges and opportunities in targeted therapy approaches, emphasizing the need for personalized medicine and data sharing to improve cancer treatment outcomes. The study demonstrates that adhesion molecule inhibitors significantly reduce cancer cell metastasis across various cancer types, with a 75% reduction in metastatic events upon treatment with integrin inhibitors. The effectiveness of these inhibitors is supported by subgroup analyses showing higher response rates in advanced stages of cancer. The review underscores the importance of prolonged treatment regimens and the need for further research to address challenges such as drug resistance, toxicity, and tumor heterogeneity. The findings highlight the potential of targeting key adhesion molecules to disrupt cancer cell-ECM interactions and control metastasis. The review also emphasizes the importance of advanced preclinical models and clinical trials in validating the efficacy of these therapies. Overall, the study provides valuable insights into the mechanisms governing cancer cell adhesion, metastasis, and inhibition, offering promising therapeutic targets for the development of more effective cancer treatments.